Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and Maya Patel unpack the patient, evidence and commercial implications.
Also covered: Talvey’s proposed earlier-line use in Europe; Arrowhead’s early ARO-MAPT tau data in healthy volunteers; Foundayo’s European committee recommendations; RYZUMVI’s presbyopia approval; China’s draft drug-technology export controls; and Labcorp’s agreement to acquire select BioReference assets.
Recorded for Friday, October 16; released October 17 after a freshness check.
Podden och tillhörande omslagsbild på den här sidan tillhör
BZ Group. Innehållet i podden är skapat av BZ Group och inte av,
eller tillsammans med, Poddtoppen.
